What iCardio.ai does

iCardio.ai is a Los Angeles-based, privately held AI company founded in 2019 that develops deep-learning software for the interpretation of echocardiograms. Its core platform, the "iCardio.ai Brain," is built on a proprietary dataset of more than 200 million ultrasound images and comprises 60+ concurrent machine-learning models that perform view classification, chamber and aortic measurements, image-quality scoring, and disease detection. The commercial portfolio centers on two FDA 510(k)-cleared products: EchoMeasure™, which automates more than a dozen cardiac measurements and preliminary reporting, and CardioVision™, which detects aortic stenosis from parasternal long-axis clips and was the first AI to receive FDA Breakthrough Device Designation for handheld ultrasound. Additional modules include EchoCheck™ for quality assurance, EchoGPT for image-to-text interpretation, AutoGeo LV for left-ventricular geometry, and AutoLabel ICE for real-time intracardiac labeling.

The company sells exclusively through B2B enterprise channels, integrating its API into PACS platforms (UltraLinQ, deepc, SARC MedIQ, HeartLab), care-coordination systems (Viz.ai), and ultrasound hardware from manufacturers such as GE Healthcare, Butterfly Network, Clarius, and Abbott. Revenue is generated through API and per-study licensing, integration and subscription fees, and custom model-development and data-annotation services. Strategic customers include Cedars-Sinai, Tufts Medical Center, and the University of Lyon for clinical research, while primary buyers are cardiology departments, hospital systems, and OEMs seeking to reduce intra-reader variability, address sonographer workload and work-related musculoskeletal disorders, and expand access to cardiac diagnostics in primary and point-of-care settings.

iCardio.ai has secured funding from BSD Enterprises, the Jerusalem Venture Partners PlayBeyondBio accelerator, the Cedars-Sinai Accelerator ($100,000), and the $1 million Roddenberry Foundation Grand Prize, and in February 2026 closed a $4.5 million financing round. The company is led by co-founder/CEO Joseph Sokol, co-founder/Chief Medical Advisor Dr. Aakriti Gupta, and co-founder/CTO Dr. Roman Sandler, with advisory support from Dr. Raj Makkar (Cedars-Sinai) and Dr. Harlan Krumholz (Yale).

Name

iCardio.ai

Legal name

iCardio.ai

Website

https://icardio.ai

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

iCardio.ai develops FDA-cleared deep-learning software that automates echocardiogram interpretation, including cardiac measurements (EchoMeasure™) and aortic stenosis detection (CardioVision™), sold via API to ultrasound OEMs, PACS providers, and healthcare systems.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), Medical Imaging AI (HDAAAEAH), Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE)

Keywords

• Echocardiography AI software
• Cardiac imaging automation
• Ultrasound AI analysis
• Structural heart detection
• Medical imaging deep learning

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AI Software Licensing: iCardio.ai licenses its FDA-cleared AI software products (EchoMeasure™ and CardioVision™) to healthcare systems, PACS vendors, and ultrasound hardware manufacturers. Revenue is generated through integration fees, API usage fees, and per-study or subscription-based licensing arrangements with enterprise customers.
2. Enterprise API Services: The company provides API access for automated echocardiographic interpretation, with EchoMeasure serving as the foundational platform for automated echo interpretation. Revenue is generated through API service fees integrated into partner platforms.
3. Data and Custom Model Development Services: iCardio.ai offers custom-tailored automated solutions, specialized datasets for clinical validation, and deployment of existing algorithms for partners. This includes anonymization services, data annotation and curation, and bespoke echocardiography model development.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

iCardio.ai develops FDA 510(k)-cleared artificial intelligence software for automated interpretation of echocardiography, including EchoMeasure™ for automated cardiac measurements and CardioVision™ for AI-driven detection of aortic stenosis from PLAX clips. The company licenses these AI tools and exposes them via REST API for integration into PACS platforms, ultrasound hardware, and care coordination systems used by hospitals, cardiology practices, and ultrasound OEMs globally.

Product overview

iCardio.ai is a platform company offering FDA-cleared AI products for echocardiography automation, centered around two core cleared products: EchoMeasure™ for automated cardiac measurements and CardioVision™ for aortic stenosis detection. These integrate with a suite of add-on modules including EchoCheck™ (image quality assessment), EchoGPT (image-to-text AI), AutoGeo LV (automated LV measurements), and AutoLabel ICE (real-time anatomical labeling). The platform is built on a proprietary database of 200M+ ultrasound images and supports enterprise data services including custom model development and clinical data annotation. Integration occurs through PACS platforms (UltraLinQ, deepc, SARC MedIQ), care coordination systems (Viz.ai), and ultrasound hardware vendors (Butterfly Network, Abbott, GE Healthcare).

Differentiator

Problem solved

Functional benefit

Brands

• EchoMeasure™: FDA 510(k) cleared AI solution for automated echocardiographic measurements, supporting a robust imaging workflow including image perspective classification, image quality assessment, and over a dozen linear and volumetric measurement estimations.
• CardioVision™
• EchoCheck™

Products and services

• EchoMeasure™ FDA 510(k)-cleared AI software that automates over a dozen cardiac linear and volumetric measurements from echocardiography, including automated ejection fraction, chamber diameters, wall thicknesses, and aortic measurements. Identifies diastolic/systolic phases and produces a fully automated echo report. Integrates into standard reporting workflows via simple REST API for PACS and hardware partners.
• CardioVision™ FDA 510(k)-cleared AI diagnostic aid for automated detection of aortic stenosis from PLAX ultrasound clips using deep learning without explicit variable measurement. Holds FDA Breakthrough Device Designation, the first granted for handheld ultrasound AI. Enables NTAP reimbursement pathway and Medicare coverage.
• Interpretations Professional echo interpretation service where echocardiograms are read by top cardiologists assisted by iCardio.ai's AI, providing comprehensive analysis that combines automated AI measurements with expert clinical review.
• Data Services Enterprise services including access to proprietary dataset of 200M+ echocardiographic images, custom model development tailored to specific clinical and research objectives, data anonymization for regulatory compliance, and data annotation/curation by clinical experts.

Quantifiable outcome

• Echocardiogram interpretation time reduced by up to 3x
• +4 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability7 records

Feature9 records

Partnerships

14 partnerships are on record, tiered core and minor.

• AbbottcoreStrategic or Co-development Partner · 16 September 2024Collaboration to develop AI applications for Abbott's electrophysiology imaging product line. iCardio.ai will support Abbott's goals of automating model creation on the EnSite X cardiac mapping system using 2D intracardiac echo (ICE) images captured by Abbott's ICE catheters.
• Cedars-Sinai AcceleratorminorStrategic or Co-development Partner · 10 September 2024iCardio.ai joined the 10th cohort of the Cedars-Sinai Accelerator, a three-month program with mentorship from 300+ clinicians and executives. Companies receive $100,000 investment and present at HLTH Event 2024 Demo Day.
• SARC MedIQcoreTechnology or Integration · 9 September 2024Strategic partnership to revolutionize distribution of AI tools by integrating iCardio.ai's technology with SARC MedIQ's state-of-the-art PACS platform. Accelerating availability of AI in cloud PACS and the broader cardiology healthcare industry.
• Viz.aicoreStrategic or Co-development Partner · 2 April 2024Partnership to advance rapid detection of aortic stenosis through integration of iCardio.ai's breakthrough ultrasound interpretation technology into Viz.ai's comprehensive Cardio Suite. Viz.ai's solutions are used by clinicians in over 1,500 healthcare institutions.
• deepccoreChannel Partner/ Reseller/ Distributor · 23 February 2024Partnership to integrate iCardio.ai's Ultrasound OS into deepcOS Radiology AI platform, providing European healthcare systems access to automated echocardiogram interpretation, perspective classification, image quality assessment, and measurement of crucial heart parameters.
• UltraLinQ Healthcare SolutionscoreTechnology or Integration · 8 January 2024Strategic partnership to integrate iCardio.ai's AI tools into UltraLinQ's cloud PACS platform. Combining automated AI tools with UltraLinQ's robust image viewer and advanced reporting platform for substantial improvements in quality, efficiency, accuracy, and speed in ultrasound image interpretation.
• Butterfly NetworkcoreTechnology or Integration · 14 November 2023iCardio.ai joined Butterfly Garden, Butterfly's AI marketplace, to deploy its cardiac AI suite on Butterfly's single-probe, whole-body handheld ultrasound system. Enables providers to take simplified echo examinations with a Butterfly probe and instantly produce fully automated echo reports.
• HeartX by HealthTech Arkansas and MedAxiomminorStrategic or Co-development Partner · 20 October 2022Accepted to HeartX 2022 accelerator cohort, receiving $150,000 investment and guaranteed pilot projects with seven Arkansas healthcare providers including Arkansas Children's Hospital, Arkansas Heart Hospital, Baptist Health, and others.
• GE HealthcarecoreStrategic or Co-development Partner · 1 June 2021Multi-year collaboration with GE Healthcare to provide AI model development services, propelled by the division for digital innovation in ultrasound. Fast-tracking bringing artificial intelligence to ultrasound applications through deep learning. This represents a vote of confidence from the world's largest ultrasound hardware vendor.
• NVIDIAcoreTechnology or IntegrationNVIDIA Inception member leveraging NVIDIA Clara Holoscan platform for real-time multi-AI processing. iCardio.ai's models featured in NVIDIA Holoscan SDK as reference application for multi-AI inference, achieving approximately 30% performance improvement.
• Tufts UniversityminorStrategic or Co-development PartnerCollaboration with Tufts University led by Dr. Benjamin Wessler on prediction of aortic stenosis with machine learning. Published peer-reviewed research in Journal of the American Society of Echocardiography.
• University of LyonminorStrategic or Co-development PartnerAcademic partnership for research and development in cardiac AI and echocardiography.
• Clarius Mobile HealthminorChannel Partner/ Reseller/ DistributorPartnership to integrate iCardio.ai's AI tools with Clarius handheld ultrasound devices (Coming soon).
• Diagnostic PartnersminorChannel Partner/ Reseller/ DistributorPartner listed in company partners section for distribution of iCardio.ai solutions.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Ultromics: UK-based AI company focused on echocardiography, with FDA-cleared products such as EchoGo for automated cardiac function analysis. Direct competitor to iCardio.ai's EchoMeasure™ with the same target customers (cardiology departments, hospitals, ultrasound OEMs) and similar AI-for-echo value proposition.
• Caption Health (now part of GE HealthCare): AI-guided ultrasound acquisition platform acquired by GE HealthCare. Direct competitor in AI-for-echocardiography guidance and measurement, with the same OEM-led distribution model; now internalized by iCardio.ai's largest partner, intensifying the partner-vs-competitor dynamic.
• EchoNous: Developer of handheld ultrasound devices (Kosmos) with embedded AI for cardiac assessment. Comparable to iCardio.ai in pursuing AI-assisted point-of-care echocardiography, though EchoNous is vertically integrated into hardware while iCardio.ai is software/AI-only.

Emerging players

• Arterys (Tempus): Cloud-native medical imaging AI platform (acquired by Tempus) that includes cardiac MRI and CT AI. Comparable in offering imaging-AI-as-a-service via cloud/API to hospitals, with overlapping enterprise PACS integration model — broader than echo but intersecting on cardiac use cases.
• Anumana: Cardiac AI company developing ECG-based and multi-modal algorithms (acquired by Tempus/nference). Comparable in targeting earlier-stage detection of structural heart disease, though via ECG rather than echocardiography — adjacent competitive pressure for the same cardiology decision-maker.
• HeartFlow: AI-driven cardiac imaging analysis focused on CT-derived FFR for coronary disease. Comparable as a SaMD cardiac imaging AI company selling to the same cardiology and hospital enterprise buyers, though HeartFlow addresses coronary rather than structural heart disease.
• Cleerly: AI platform for cardiac CT angiography analysis to quantify plaque and stenosis. Comparable as a venture-backed cardiac imaging AI company pursuing enterprise hospital sales and reimbursement pathways (including CPT codes), though addressing coronary rather than valvular disease.
• Inheart: AI-enabled cardiac mapping and electrophysiology imaging company. Comparable to iCardio.ai's AutoLabel ICE and Abbott collaboration in applying AI to intracardiac echo for electrophysiology procedures, though focused on a narrower procedural use case.

Broad incumbents

• Philips (Cardiac Ultrasound / HeartModel): Global incumbent in cardiac ultrasound with HeartModel AI for automated echo quantification. Competes with iCardio.ai at the OEM layer with a vertically integrated hardware+AI offering, but lacks iCardio.ai's hardware-agnostic API approach.
• Siemens Healthineers (Cardiac Ultrasound AI): Major ultrasound OEM with embedded AI features in its ACUSON cardiac ultrasound line. Competes with iCardio.ai for AI-on-ultrasound budgets, especially in European and emerging markets where Siemens has strong installed bases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/19196888

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iCardio.ai